English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, February 21, 2018
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Friday, February 16, 2018
エーザイ、英国NICEが抗がん剤「レンビマ」を甲状腺がん治療薬として推奨
Thursday, January 18, 2018
エーザイ、制吐剤「ALOXI(R)」に関する米国の特許侵害訴訟について
Friday, February 16, 2018
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Tuesday, February 13, 2018
エーザイ、抗がん剤レンバチニブ 肝細胞がんにおける臨床第III相試験結果がThe Lancetに掲載
Monday, February 12, 2018
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Thursday, February 1, 2018
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
エーザイ、パーキンソン病治療剤サフィナミドが国内臨床第II/III相試験において主要評価項目を達成
Monday, January 22, 2018
エーザイ、「レンビマ(R)」(レンバチニブ)の肝細胞がんを対象とした臨床第III相試験について独立画像判定に基づく解析結果を米国臨床腫瘍学会 消化器がんシンポジウムにて発表
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575